Do analysts recommend ATHE or IMNN?

Imunon has a consensus price target of $10.00, indicating a potential upside of 369.48%. Given Imunon's higher probable upside, analysts clearly believe Imunon is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, ATHE or IMNN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Imunon N/A N/A -$14.49M -$5.16 N/A

Is ATHE or IMNN more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Imunon N/A -341.23% -153.79%

Do analysts prefer IMNN or LITS?

Imunon presently has a consensus target price of $10.00, indicating a potential upside of 369.48%. Given Imunon's stronger consensus rating and higher possible upside, research analysts plainly believe Imunon is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IMNN or LITS more profitable?

Lite Strategy's return on equity of -90.81% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -341.23% -153.79% Lite Strategy N/A -90.81% -89.33%

Is IMNN or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -341.23% -153.79% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media refer more to IMNN or ATNM?

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than Imunon. MarketBeat recorded 6 mentions for Actinium Pharmaceuticals and 2 mentions for Imunon. Imunon's average media sentiment score of 0.93 beat Actinium Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ADXS or IMNN?

Imunon has a consensus price target of $10.00, indicating a potential upside of 369.48%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ADXS or IMNN more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Imunon N/A -341.23% -153.79%

Is ALGS or IMNN more profitable?

Imunon has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -1,919.68% -139.47% -90.88% Imunon N/A -341.23% -153.79%

Imunon (IMNN) Competitors

$2.13 -0.01 (-0.23%)

As of 01:58 PM Eastern

Compare

IMNN vs. ATHE, LITS, ATNM, ADXS, and ALGS

Should you buy Imunon stock or one of its competitors? MarketBeat compares Imunon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Imunon include Alterity Therapeutics (ATHE), Lite Strategy (LITS), Actinium Pharmaceuticals (ATNM), Ayala Pharmaceuticals (ADXS), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry.

How does Imunon compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Alterity Therapeutics' return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Imunon	N/A	-341.23%	-153.79%

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 2 articles in the media. Alterity Therapeutics' average media sentiment score of 1.43 beat Imunon's score of 0.93 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alterity Therapeutics	Positive
Imunon	Positive

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

Imunon has a consensus price target of $10.00, indicating a potential upside of 369.48%. Given Imunon's higher probable upside, analysts clearly believe Imunon is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alterity Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Imunon has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market.

Summary

Alterity Therapeutics beats Imunon on 5 of the 8 factors compared between the two stocks.

How does Imunon compare to Lite Strategy?

Imunon (NASDAQ:IMNN) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

In the previous week, Imunon had 1 more articles in the media than Lite Strategy. MarketBeat recorded 2 mentions for Imunon and 1 mentions for Lite Strategy. Lite Strategy's average media sentiment score of 1.87 beat Imunon's score of 0.93 indicating that Lite Strategy is being referred to more favorably in the news media.

Company	Overall Sentiment
Imunon	Positive
Lite Strategy	Very Positive

Imunon has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

4.5% of Imunon shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 2.8% of Imunon shares are owned by insiders. Comparatively, 1.6% of Lite Strategy shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Imunon presently has a consensus target price of $10.00, indicating a potential upside of 369.48%. Given Imunon's stronger consensus rating and higher possible upside, research analysts plainly believe Imunon is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Imunon has higher earnings, but lower revenue than Lite Strategy. Lite Strategy is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A
Lite Strategy	$65.30M	0.43	-$15.94M	-$1.60	N/A

Lite Strategy's return on equity of -90.81% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-341.23%	-153.79%
Lite Strategy	N/A	-90.81%	-89.33%

Summary

Imunon beats Lite Strategy on 8 of the 14 factors compared between the two stocks.

How does Imunon compare to Actinium Pharmaceuticals?

Imunon (NASDAQ:IMNN) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Actinium Pharmaceuticals' return on equity of -100.85% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-341.23%	-153.79%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

4.5% of Imunon shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 2.8% of Imunon shares are held by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than Imunon. MarketBeat recorded 6 mentions for Actinium Pharmaceuticals and 2 mentions for Imunon. Imunon's average media sentiment score of 0.93 beat Actinium Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Imunon has higher earnings, but lower revenue than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A
Actinium Pharmaceuticals	$90K	413.10	-$48.82M	-$0.75	N/A

Imunon currently has a consensus price target of $10.00, suggesting a potential upside of 369.48%. Actinium Pharmaceuticals has a consensus price target of $4.50, suggesting a potential upside of 279.75%. Given Imunon's higher possible upside, research analysts clearly believe Imunon is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Imunon has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Summary

Actinium Pharmaceuticals beats Imunon on 8 of the 14 factors compared between the two stocks.

How does Imunon compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Ayala Pharmaceuticals' return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Imunon	N/A	-341.23%	-153.79%

In the previous week, Imunon had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Imunon and 0 mentions for Ayala Pharmaceuticals. Imunon's average media sentiment score of 0.93 beat Ayala Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Imunon	Positive

Imunon has lower revenue, but higher earnings than Ayala Pharmaceuticals. Imunon is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

Imunon has a consensus price target of $10.00, indicating a potential upside of 369.48%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Imunon has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market.

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Imunon beats Ayala Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Imunon compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aligos Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market. Comparatively, Imunon has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

Aligos Therapeutics currently has a consensus target price of $38.50, suggesting a potential upside of 646.12%. Imunon has a consensus target price of $10.00, suggesting a potential upside of 369.48%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 2 articles in the media. Aligos Therapeutics' average media sentiment score of 1.22 beat Imunon's score of 0.93 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Imunon	Positive

Imunon has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Imunon	N/A	-341.23%	-153.79%

Imunon has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.58	-$24.19M	-$8.69	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

Summary

Aligos Therapeutics beats Imunon on 11 of the 15 factors compared between the two stocks.

Get Imunon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNN vs. The Competition

Export

Metric	Imunon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.95M	$3.26B	$6.26B	$12.40B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-0.41	17.82	22.37	24.16
Price / Sales	N/A	321.51	547.57	124.65
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	0.93	6.55	9.79	6.69
Net Income	-$14.49M	$24.20M	$3.56B	$336.98M
7 Day Performance	-7.39%	-3.19%	-1.27%	0.45%
1 Month Performance	-23.93%	0.39%	3.58%	4.95%
1 Year Performance	-92.57%	46.56%	27.13%	34.01%

Imunon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNN Imunon	3.6371 of 5 stars	$2.14 -0.2%	$10.00 +368.4%	-94.3%	$8.97M	N/A	N/A	30
ATHE Alterity Therapeutics	1.3243 of 5 stars	$4.08 -1.4%	N/A	-12.7%	$36.71M	N/A	N/A	10	Short Interest Decrease Gap Up
LITS Lite Strategy	1.1546 of 5 stars	$1.05 -1.9%	N/A	N/A	$36.41M	$65.30M	N/A	100	Positive News Analyst Forecast High Trading Volume
ATNM Actinium Pharmaceuticals	2.2693 of 5 stars	$1.16 -1.7%	$4.50 +287.9%	-24.1%	$36.40M	$90K	N/A	30	News Coverage
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNN) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Imunon (IMNN) Competitors

IMNN vs. ATHE, LITS, ATNM, ADXS, and ALGS

How does Imunon compare to Alterity Therapeutics?

Summary

How does Imunon compare to Lite Strategy?

Summary

How does Imunon compare to Actinium Pharmaceuticals?

Summary

How does Imunon compare to Ayala Pharmaceuticals?

Summary

How does Imunon compare to Aligos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Imunon (IMNN) Competitors

IMNN vs. ATHE, LITS, ATNM, ADXS, and ALGS

How does Imunon compare to Alterity Therapeutics?

Is ATHE or IMNN more profitable?

Does the media prefer ATHE or IMNN?

Do institutionals and insiders believe in ATHE or IMNN?

Which has stronger valuation & earnings, ATHE or IMNN?

Do analysts recommend ATHE or IMNN?

Which has more volatility & risk, ATHE or IMNN?

Summary

How does Imunon compare to Lite Strategy?

Does the media prefer IMNN or LITS?

Which has more risk & volatility, IMNN or LITS?

Do institutionals and insiders have more ownership in IMNN or LITS?

Do analysts prefer IMNN or LITS?

Which has preferable valuation and earnings, IMNN or LITS?

Is IMNN or LITS more profitable?

Summary

How does Imunon compare to Actinium Pharmaceuticals?

Is IMNN or ATNM more profitable?

Do insiders & institutionals have more ownership in IMNN or ATNM?

Does the media refer more to IMNN or ATNM?

Which has preferable earnings and valuation, IMNN or ATNM?

Do analysts prefer IMNN or ATNM?

Which has more risk and volatility, IMNN or ATNM?

Summary

How does Imunon compare to Ayala Pharmaceuticals?

Is ADXS or IMNN more profitable?

Does the media prefer ADXS or IMNN?

Which has preferable valuation and earnings, ADXS or IMNN?

Do analysts prefer ADXS or IMNN?

Which has more risk & volatility, ADXS or IMNN?

Do institutionals and insiders have more ownership in ADXS or IMNN?

Summary

How does Imunon compare to Aligos Therapeutics?

Do insiders & institutionals hold more shares of ALGS or IMNN?

Which has more risk & volatility, ALGS or IMNN?

Do analysts recommend ALGS or IMNN?

Does the media prefer ALGS or IMNN?

Is ALGS or IMNN more profitable?

Which has stronger earnings & valuation, ALGS or IMNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools